Appendicular lean mass linked to decrease in Alzheimer’s risk
Jul 10, 2023
A higher appendicular lean mass also was associated with increased cognitive performance.
FDA gives full approval to Alzheimer’s disease drug Leqembi
Jul 06, 2023
Although Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds.
New law implements training, exam requirements for assisted living employees
By
Lois A. Bowers
Jun 27, 2023
A new law in Texas requires managers and caregivers at assisted living communities serving people living with dementia to complete four hours of dementia-related training and pass an exam about dementia,...
Gut microbial taxonomic profiles differ with, without preclinical Alzheimer’s disease
Jun 16, 2023
A change in gut microbiome composition was associated with β-amyloid and tau pathological brain biomarkers.
Failing to cover Alzheimer’s therapies a costly proposition: researchers
By
Kimberly Bonvissuto
Jun 16, 2023
Not managing Alzheimer’s disease and related dementias is a costly proposition not just to families, but also to society, according to two recent studies.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
CMS announces Alzheimer’s drug coverage policy, but ‘the devil is in the details,’ experts say
By
Kimberly Bonvissuto
Jun 01, 2023
A Thursday announcement by the Centers for Medicare & Medicaid Services regarding coverage of Alzheimer’s drugs is being met with skepticism by some industry advocates who say that “the devil is in...
Causal link ID’d for Alzheimer’s disease, generalized epilepsy
May 25, 2023
A genetic predisposition to Alzheimer’s also is linked to an increased risk of focal epilepsy with hippocampal sclerosis.
Allopurinol may cut risk for neurodegenerative diseases
May 19, 2023
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636